|
Sorted by: Date | Top Results
|
|
Author |
|
Date |
| |
| |
| 1. |
Forget the Bollinger bands; FDA won&&39;t approve 
I bought at 25 and completely divested today at a loss.
I count my blessings for the shorts who ran it up
.
Business & Finance > Investments > Stocks (A to Z) > Stocks A >
Affymax, Inc. (AFFY)
|
|
annt2001 |
|
22-Sep-09 01:30 am |
| |
| 2. |
Cut your losses....Hematide is a loser
There's too much scrutiny regarding ESA's and
cardiovascular effects...this product won't make
the grade
Business & Finance > Investments > Stocks (A to Z) > Stocks A >
Affymax, Inc. (AFFY)
|
|
annt2001 |
|
19-Sep-09 01:41 am |
| |
| 3. |
I wish this drug was a winner, but it&&39;s not
I'm sorry, this country is still in a downward
spiral, and I want to save smart investors from the
nightmare of the sudden downturn. The drug won't
make it to market. Takeda is ready to bug out. I.
..
Business & Finance > Investments > Stocks (A to Z) > Stocks A >
Affymax, Inc. (AFFY)
|
|
annt2001 |
|
18-Sep-09 09:37 pm |
| |
| 4. |
Hematide won&&39;t meet safety, efficacy endpoints
I backpedalled out. I don't want anyone else to
be duped.
Business & Finance > Investments > Stocks (A to Z) > Stocks A >
Affymax, Inc. (AFFY)
|
|
annt2001 |
|
17-Sep-09 10:05 pm |
| |
| 5. |
Big problems with Hematide
Hematide has shown no superior effects over Procrit,
Aranesp and Epogen that would substantiate approval.
In fact, it's apparent in phase III that it is
inferior to current ESA's on the...
Business & Finance > Investments > Stocks (A to Z) > Stocks A >
Affymax, Inc. (AFFY)
|
|
annt2001 |
|
15-Sep-09 11:20 pm |
| |